Cluster for atherothrombosis and individualized medicine (curATime)

© TRON gGmbH

The next generation innovation network curATime aims to develop tailored treatment methods and prevention concepts for cardiovascular diseases using artificial intelligence (AI) in biomarker research and immunological methods.

Using AI to combat cardiovascular diseases

Cardiovascular diseases are the leading cause of death worldwide. Atherothrombosis underlies almost all cardiovascular diseases.

The vision of curATime is to selectively intervene immunotherapeutically based on an improved understanding of the physical processes that together lead to the onset and development of the disease. The technologies developed by curATime partners in the area of "ribopharmaceuticals" known from mRNA vaccines and artificial intelligence (AI), coupled with one of the best centers for thrombosis research and access to extensive data and biobanks, offer great potential in the treatment of cardiovascular disease.

Excellent synergies against atherothrombosis

curATime combines experts from biomarker and thrombosis research, clinical cardiology, immunotherapy, epidemiology and machine learning. With their expertise and access to extensive population studies and disease cohorts, the core partners (TRON gGmbH, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Deutsches Forschungszentrum für Künstliche Intelligenz) have the best prerequisites to achieve the goals of the cluster.

Clusters4Future - curATime selected as next generation innovation network

The course for curATime was set in November 2020 within the second round of the Clusters4Future competition organised by the BMBF. In September 2021, after a multi-step process, curATime made it into the already funded conception phase and was selected in July 2022 as one of seven clusters in the second round of competition. In 2023, the funded initial three-year implementation phase started.